A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy

Matteo Ferro, Giuseppe Lucarelli, Ottavio de Cobelli, Pasquale Dolce, Daniela Terracciano, Gennaro Musi, Angelo Porreca, Gian Maria Busetto, Francesco Del Giudice, Francesco Soria, Paolo Gontero, Francesco Cantiello, Rocco Damiano, Fabio Crocerossa, Abdal Rahman Abu Farhan, Riccardo Autorino, Mihai Dorin Vartolomei, Michele Marchioni, Andrea Mari, Andrea MinerviniNicola Longo, Giuseppe Celentano, Francesco Chiancone, Sisto Perdonà, Paola Del Prete, Pasquale Ditonno, Michele Battaglia, Stefania Zamboni, Alessandro Antonelli, Francesco Greco, Giorgio Ivan Russo, Rodolfo Hurle, Nicolae Crisan, Matteo Manfredi, Francesco Porpiglia, Dario Ribera, Pietro De Placido, Sergio Facchini, Luca Scafuri, Antonio Verde, Giuseppe Di Lorenzo, Vincenzo Cosimato, Angelo Luciano, Vincenzo Francesco Caputo, Felice Crocetto, Carlo Buonerba

Research output: Contribution to journalArticlepeer-review

Abstract

The objective of the current research was to explore the potential prognostic value of readily available clinical and pathologic variables in bladder cancer. The novel association found between cholesterol levels and prognosis may provide the rationale for exploring novel treatments. Patients included had histologically confirmed urothelial bladder cancer and were treated with at least 3 cycles of cisplatin-based neoadjuvant chemotherapy before radical cystectomy with lymphadenectomy. A total of 245 patients at low, intermediate and high risk, presenting with 0-1, 2 or 3-4 risk factors, including positive lymph nodes, Hb
Original languageEnglish
Pages (from-to)3987-3994
Number of pages8
JournalFuture Oncol.
Volume17
Issue number30
DOIs
Publication statusPublished - Oct 2021

Fingerprint

Dive into the research topics of 'A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy'. Together they form a unique fingerprint.

Cite this